A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the efficacy and safety of standard chemotherapy
regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive
pulmonary tuberculosis.